Immunocore Holdings PLC (IMCR) — SEC Filings
Immunocore Holdings PLC (IMCR) — 50 SEC filings. Latest: 8-K (May 6, 2026). Includes 25 8-K, 8 SC 13G/A, 7 10-Q.
View Immunocore Holdings PLC on SEC EDGAR
Overview
Immunocore Holdings PLC (IMCR) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Nov 28, 2025: Immunocore Holdings plc filed an 8-K on November 28, 2025, reporting changes as of November 26, 2025. The filing pertains to the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. Specific de
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 5 bullish, 42 neutral, 3 mixed. The dominant filing sentiment for Immunocore Holdings PLC is neutral.
Filing Type Overview
Immunocore Holdings PLC (IMCR) has filed 25 8-K, 7 10-Q, 2 DEF 14A, 2 10-K, 8 SC 13G/A, 4 SC 13G, 2 SC 13D/A with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of IMCR's 32 recent filings, 0 were flagged as high-risk, 12 as medium-risk, and 20 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $103,693,000 |
| Net Income | ($177,000) |
| EPS | N/A |
| Debt-to-Equity | 1.78 |
| Cash Position | $498,413,000 |
| Operating Margin | -6.9% |
| Total Assets | $1,102,500,000 |
| Total Debt | $392,587,000 |
Key Executives
- Dr. Joern Hoch
- Ms. Sarah O'Connor
- Dr. Joanna Horobin
- Dr. Richard J. Davies
- Professor Sir John Bell
Industry Context
Immunocore operates in the highly competitive and rapidly evolving biotechnology sector, specifically focusing on oncology and infectious diseases. The industry is characterized by significant R&D investment, long development cycles, and stringent regulatory hurdles. Success hinges on innovative therapeutic platforms like ImmTAX and the ability to navigate complex global markets for drug approvals and commercialization.
Top Tags
8-K (6) · biotech (6) · filing (5) · corporate-governance (4) · Biotechnology (4) · financial-reporting (4) · financials (4) · financial-condition (3) · 10-Q (3) · Revenue Growth (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Nominal Value per Ordinary Share | 0.002 | This is the stated nominal value of each ordinary share of Immunocore Holdings plc. |
| Revenue from sale of therapies | $103.693M | Increased 29.2% for Q3 2025 compared to Q3 2024 |
| Net loss | ($0.177M) | For the three months ended September 30, 2025, a shift from net income |
| Research and development expense | $70.572M | Increased 33.7% for Q3 2025, reflecting pipeline investment |
| Cash and cash equivalents | $498.413M | As of September 30, 2025, indicating strong liquidity |
| Countries | 28 | KIMMTRAK commercially launched in 28 countries |
| Ordinary shares outstanding | 50,530,419 | As of October 31, 2025 |
| Total Revenue | $115.0M | Increased 35.3% from $85.0M in H1 2024 to $115.0M in H1 2025. |
| Collaboration Revenue | $60.0M | Surged from $35.0M in H1 2024 to $60.0M in H1 2025. |
| Sale of Therapies Revenue | $55.0M | Grew from $50.0M in H1 2024 to $55.0M in H1 2025. |
| Net Income | $20.0M | Swung from a net loss of $10.0M in H1 2024 to a net income of $20.0M in H1 2025. |
| Revenue Growth Rate | 35.3% | Percentage increase in total revenue from H1 2024 to H1 2025. |
| Reporting Period | Q1 2025 | First quarter of 2025 financial performance |
| Balance Sheet Date | 2024-12-31 | Financial position as of year-end 2024 |
| Filing Date | 20250404 | Date the definitive proxy statement was filed with the SEC. |
Forward-Looking Statements
- {"claim":"Immunocore's stock may see increased investor interest due to Wellington's disclosed stake.","entity":"Immunocore Holdings plc","targetDate":"Q2 2024","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Immunocore Holdings PLC (IMCR)?
Immunocore Holdings PLC has 50 recent SEC filings from Jan 2024 to May 2026, including 25 8-K, 8 SC 13G/A, 7 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of IMCR filings?
Across 50 filings, the sentiment breakdown is: 5 bullish, 42 neutral, 3 mixed. The dominant sentiment is neutral.
Where can I find Immunocore Holdings PLC SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Immunocore Holdings PLC (IMCR) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Immunocore Holdings PLC?
Key financial highlights from Immunocore Holdings PLC's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for IMCR?
The investment thesis for IMCR includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Immunocore Holdings PLC?
Key executives identified across Immunocore Holdings PLC's filings include Dr. Joern Hoch, Ms. Sarah O'Connor, Dr. Joanna Horobin, Dr. Richard J. Davies, Professor Sir John Bell.
What are the main risk factors for Immunocore Holdings PLC stock?
Of IMCR's 32 assessed filings, 0 were flagged high-risk, 12 medium-risk, and 20 low-risk.
What are recent predictions and forward guidance from Immunocore Holdings PLC?
Recent forward-looking statements from Immunocore Holdings PLC include guidance on {"claim":"Immunocore's stock may see increased investor interest due to Wellington's disclosed stake.","entity":"Immunoc.